Crescent Biopharma develops innovative cancer therapies to treat solid tumors. Self-described as pioneering in this field.

Crescent Biopharma

Crescent Biopharma | 451 followers on LinkedIn. Illuminating a brighter future for treating solid tumors with potentially best-in-class therapies.

Interim CEO

Jonathan Violin

Chief Business Officer

Chris Doughty

📢 NEWS: GlycoMimetics has announced an agreement to acquire Crescent Biopharma and advance Crescent’s portfolio of novel biologics precision engineered to improve outcomes for patients with solid tumors — delivering superior efficacy to the current gold standard. Upon completion of the merger, the unified company will operate as Crescent, progressing lead assets CR-001, a cooperative PD-1 x VEGF bispecific antibody and CR-002, an antibody-drug conjugate for an undisclosed target with a topoisomerase inhibitor payload that may offer best-in-class efficacy. With a concurrent private financing of approximately $200 million led by Fairmount Funds Management LLC , Venrock , BVF PARTNERS, L.P , and a large investment management firm, Crescent expects to fund operations through 2027. Read the release here: https://lnkd.in/eHRSNgjp Learn more at www.crescentbiopharma.com . #SolidTumors #Oncology #CancerCare #Merger #Biotech

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 6, 2024 10:59 PM	cb1ed7be
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 10:59 PM	57d82055
crunchbase trigger	general	Nov 6, 2024 10:59 PM	1136093a
crunchbase profile	general	Nov 7, 2024 4:55 PM	3eb30640
li profile	general	Nov 6, 2024 10:59 PM	0a2db62f
translate crunchbase fundingrounds	general
peers	general	Nov 6, 2024 10:59 PM	59aaeff4
news basic	general	Nov 6, 2024 10:59 PM	320bca6a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CRES

COM:CRESCENTBIOPHARMA

Crescent Biopharma